|
"carlesi r"的相關文件
顯示項目 1-4 / 4 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2021-10 |
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study
|
Valle, JW;Vogel, A;Denlinger, CS;He, AR;Bai, LY;Orlova, R;Van Cutsem, E;Adeva, J;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, H;Girvan, AC;Zhang, W;Liu, JG;Tang, CL;Ebert, PJ;Aggarwal, A;McNeely, SC;Moser, BA;Oliveira, JM;Carlesi, R;Walgren, RA;Oh, DY |
| 臺大學術典藏 |
2021-01-28T01:06:25Z |
Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review
|
Chen L.-T.;Oh D.-Y.;Ryu M.-H.;Kun-Huei Yeh;Yeo W.;Carlesi R.;Cheng R.;Kim J.;Orlando M.;Kang Y.-K.; Chen L.-T.; Oh D.-Y.; Ryu M.-H.; KUN-HUEI YEH; Yeo W.; Carlesi R.; Cheng R.; Kim J.; Orlando M.; Kang Y.-K. |
| 國家衛生研究院 |
2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
|
Valle, JW;Bai, LY;Orlova, R;Van Cutsem, E;Alfonso, JA;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, HS;Denlinger, CS;Vogel, A;He, AR;Bousmans, N;Girvan, AC;Zhang, W;Walgren, RA;Carlesi, R;Oh, DY |
| 國家衛生研究院 |
2017-10 |
Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review
|
Chen, LT;Oh, DY;Ryu, MH;Yeh, KH;Yeo, W;Carlesi, R;Cheng, R;Kim, J;Orlando, M;Kang, YK |
顯示項目 1-4 / 4 (共1頁)
1
每頁顯示[10|25|50]項目
|
